Cannabis Report
Home > Boards > US OTC > Biotechs > CYTODYN INC (CYDY)

N =50 is a compromise from statistical significance

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
pearsby09 Member Profile
Member Level 
Followed By 26
Posts 3,680
Boards Moderated 0
Alias Born 04/29/16
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/15/2018 7:49:45 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/15/2018 7:44:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:04:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 6:03:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:59:49 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:57:13 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:56:30 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:56:05 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:55:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2018 5:54:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2018 4:24:25 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/22/2018 8:16:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/22/2018 7:46:52 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/22/2018 7:45:17 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/8/2018 4:06:32 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 5/4/2018 10:54:38 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/26/2018 5:09:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/11/2018 6:09:06 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/9/2018 4:34:49 PM
Amended Tender Offer Statement by Issuer (sc To-i/a) Edgar (US Regulatory) - 3/26/2018 5:27:48 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 5:25:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/26/2018 8:02:44 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/26/2018 6:02:12 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/23/2018 4:28:34 PM
pearsby09 Member Level  Friday, 11/10/17 01:27:26 PM
Re: None
Post # of 23506 
N =50 is a compromise from statistical significance to clinical significance, and even 50 is not a compelling data base for any analysis. PRO 140 IMO, will be the eighth choice on an ever revolving HAART approach. Physicians will be very reticent in adopting a N=50 drug before trying all the established HAART combinations. Habit and comfort precedes PRO 140, especially with a N=50 data base.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist